Joel Phillips, MD
Allergy & Immunology · Clearwater, FLNPI 1083724207
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 280 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,317 and has fallen 98.2% since, to $23 in 2025. That places this record below the midpoint for allergy & immunology clinicians in FL, where the typical reported total is $5,220.
Across 280 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$867
- Takeda Pharmaceuticals U.S.A., Inc.$580
- Sanofi$564
- Novartis$325
- Regeneron Healthcare Solutions, Inc.$270
- plus $2K from 20 others
What the payments were for
- Consulting fees$200%
- Food & beverage$5,411100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 79 | $1,225 |
| AstraZeneca | 50 | $867 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $580 |
| Sanofi | 21 | $564 |
| Novartis | 14 | $325 |
| Regeneron Healthcare Solutions, Inc. | 13 | $270 |
| CSL Behring | 13 | $250 |
| Teva Pharmaceuticals USA, Inc. | 15 | $245 |
| Midsouth Orthopedics Inc. | 2 | $218 |
| Amgen(2 entities) | 10 | $197 |
| Novo Nordisk | 7 | $145 |
| Genentech USA, Inc. | 5 | $91 |
| Grifols USA, LLC | 6 | $88 |
| Pfizer | 3 | $60 |
| Boehringer Ingelheim | 2 | $57 |
| Biocryst US Sales Co., LLC | 2 | $40 |
| Shire North American Group Inc | 2 | $38 |
| Optinose US, Inc. | 2 | $36 |
| Lucid Diagnostics Inc. | 1 | $22 |
| ADMA Biomanufacturing LLC | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Incyte Corporation | 1 | $18 |
| Kaleo, Inc. | 1 | $16 |
| AbbVie | 1 | $14 |
| Alk-abello, Inc | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
How this compares
$5,430 in reported general payments places this provider in the 50th percentile of 204 allergy & immunology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 47 | $160,260 |
| Dupixent SyringeDupilumab | 19 | $76,288 |
| NucalaMepolizumab | 21 | $73,356 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $59,615 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 11 | $25,366 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $20,553 |
| Arnuity ElliptaFluticasone Furoate | 43 | $15,051 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $11,172 |
| Fluticasone Propionate HfaFluticasone Propionate | 29 | $10,121 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 42 | $9,198 |
| Qvar RedihalerBeclomethasone Dipropionate | 30 | $9,159 |
| Wixela InhubFluticasone Propion/Salmeterol | 43 | $5,562 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $3,506 |
| Fluticasone Propionate | 199 | $3,107 |
| Prednisone | 384 | $2,089 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,225 | $168,575163 claims |
| Grifols USA, LLCGamunex-C | $88 | $25,36611 claims |
| AstraZenecaSymbicort | $867 | $11,17242 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $245 | $9,15930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 204 allergy & immunology providers in Florida.
Other allergy & immunology in Clearwater
- Dennis LedfordTampa$1.2M
- Nina RamirezMiami$833K
- Thomas WestbrookPensacola$810K
- Shahnaz FattehPlantation$677K
- Thomas CasaleTampa$382K
- Thomas JohnsonGainesville$361K
- Mark GlaumTampa$337K
- Alan HalseyValrico$243K
- Steve DormanJacksonville$208K
- Juan Carlos CardetTampa$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.